Patients with treatment-naïve, early-stage or isolated parenchymal recurrent NSCLC benefit from the addition of immunotherapy to stereotactic ablative radiotherapy, indicate phase 2 results.

For trials with multiple cohorts and entrance criteria, this article reports only for patients with locally advanced or metastatic urothelial carcinoma receiving second-line or later immunotherapy.

The overall survival benefit offered by immune checkpoint inhibitors in people with advanced non-small-cell lung cancer varies by age, suggests a real-world study.

medwireNews : ESMO has released an updated version of its Clinical Practice Guideline for the management of immunotherapy-related toxicities in people with cancer.

Among patients with metastatic clear cell renal cell carcinoma, the outcomes of second-line treatment are similar irrespective of whether they received dual immunotherapy or IO plus a tyrosine kinase inhibitor in the first line, indicates a chart review.

ESMO 2022 news: Advanced RCC PFS boost with addition of cabozantinib to first-line dual immunotherapy.

The treatment landscape of advanced urothelial carcinoma has changed considerably in the past few years, with immunotherapy becoming a key component.

Data from the BFAST study suggest that blood-based tumor mutational burden at a cutoff of 16 mutations does not predict first-line atezolizumab outcomes in people with advanced non-small-cell lung cancer.

A US National Cancer Database analysis suggests that immunotherapy after chemoradiotherapy for unresectable stage III non-small-cell lung cancer is associated with an overall survival benefit in the general US population.

US FDA immunotherapy approval led to a significant increase in use, but did not eliminate socioeconomic disparities among users that were apparent prior to approval, study findings indicate.

Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

Overall survival with first-line chemoimmunotherapy may be similar to that with immunotherapy alone among patients with advanced non-small-cell lung cancer and PD-L1 expression levels of at least 50%, pooled study data suggest.

Gulley Abstract Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade.

Zitvogel et al therefore conclude: “It may be of utmost importance to [immunotherapy] patients, risk-stratified on the basis of shot-gun metagenomics (rather than by 16S rRNA) sequencing, to precisely quantify the relative abundance of Akk in addition to [antibiotic] use and PD-L1 expression in patients with NSCLC in prospective trials designed to discover optimal biomarkers.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Nat Med 2022; doi:10.1038/s41591-021-01655-5

Michiel Van der Heijden and Ignacio Durán Martínez share their thoughts on the use of maintenance therapy after first-line chemotherapy for metastatic urothelial cancer and discuss new strategies in first line, such as single agent immunotherapy compared with chemotherapy and chemo-immuno combinations.

Escherichia-Shigella and Akkermansia may have specific effects on PD-1 inhibitory immunotherapy for NSCLC.

Treatment with immune checkpoint inhibitors may improve the overall survival of people with metastatic small-cell urothelial cancer, suggests a chart review.

Real-world study data show that first-line immunotherapy alone or in combination with targeted therapy is associated with better overall survival than targeted therapy alone in people with metastatic clear cell renal cell carcinoma.

The outcomes of treatment-naïve, advanced non-small-cell lung cancer patients with tumor PD-L1 levels of 1–49% may be better with the combination of chemotherapy and immunotherapy than immunotherapy alone, suggests a pooled analysis by the US FDA.